key: cord-0959045-apblf80y authors: Sayar, Zara; Moll, Rachel; Isenberg, David; Cohen, Hannah title: Thrombotic Antiphospholipid Syndrome: a practical guide to diagnosis and management date: 2020-10-15 journal: Thromb Res DOI: 10.1016/j.thromres.2020.10.010 sha: de95e079a2bc93f3eea78c00add9735874b7aa9e doc_id: 959045 cord_uid: apblf80y Thrombotic antiphospholipid syndrome (APS) is characterised by venous, arterial or microvascular thrombosis in the context of persistently positive antiphospholipid antibodies (aPL). The diagnosis and management of thrombotic APS continues to prove challenging for clinicians. We provide a practical guide to the diagnosis of APS including who to test for aPL and which tests to do. We also consider clinical practice points on the management of venous, arterial and small vessel thrombosis, in the context of first and recurrent thrombotic events. Non-criteria manifestations of APS are reviewed. An approach to recurrent thrombosis and anticoagulant-refractory APS is discussed, with options including increasing the anticoagulation intensity of vitamin K antagonists, switching to low-molecular-weight-heparin, the use of fondaparinux and/or the addition of antiplatelet treatment. The use of adjunctive options such as vitamin D, hydroxychloroquine and statins are also addressed. proteins. Anti-β2GP1 appears to play a particularly important role. 16 A key initiating pathogenic process is the exposure of negatively charged endothelial surface phospholipid. Exogenous and circulating β2GP1 can bind to this phospholipid surface and change its conformation, exposing a cryptic Arg39-Arg43 epitope in domain I that is recognised by pathologic aPL. 17, 18 The aPL-β2GP1 complex can bind to and activate endothelial cells, platelets and monocytes 19 and aPL binding can upregulate monocyte expression of tissue factor, a potent initiator of coagulation. 20 Other mechanisms include aPL interfering with the activated protein C pathway leading to acquired resistance to APC in vitro and aPL-induced decreased fibrinolysis. 21 Neutrophils play a role in arterial and venous thrombosis through the extracellular release of material, mainly DNA and histones, known as neutrophil extracellular traps (NETs). 22 Mice treated with APS IgG develop thrombi rich in NETs. 22 APL can activate the complement cascade. Blocking C3 and C5 activation in mice appears to block aPL induced thrombosis. 23 In this review, we summarise current approaches to the diagnosis and management of thrombotic APS, with suggested clinical practice points based on available guidance, evidence and clinical experience. Antiphospholipid antibody testing should be performed when there are clinical features suggestive of APS. Guidance on this topic is available from the British Society for Haematology (BSH) and ISTH. 24,25 Suggested indications for aPL testing include patients with recurrent thrombosis unexplained by subtherapeutic anticoagulation, patient non-adherence or malignancy as well as and thrombosis in unusual sites (i.e other than lower limb DVT or PE). Following a provoked VTE where test appears to predict an increased risk of recurrence in patients with a first VTE, however, the quality of evidence was very low. 26 A more recent prospective study suggested that aPL and raised D-dimer levels are independent risk factors for recurrence after a first unprovoked VTE. 27 The risk of recurrent thrombosis following a provoked first VTE associated with aPL and the duration of anticoagulation in this situation is undefined. APL testing should be considered in younger patients (<50 years) with ischaemic stroke, transient ischaemic attack or other evidence of brain ischaemia and may be useful in new stroke patients in whom APS is clinically suspected, to decide whether the patient would benefit from an anticoagulant rather than antiplatelet therapy, current standard care. 28 Conventional cardiovascular risk factors may be present in patients with APS-related stroke. The adjusted Global APS score (aGAPSS) incorporates independent cardiovascular risk factors along with aPL status could aid risk stratification based on the likelihood of recurrent arterial thrombosis. 29 Which aPL tests to do and when Table 1 provides a summary of the aPL tests that should be performed. Confirmation of a diagnosis of APS requires demonstration of persistent aPL, on two occasions, at least 12 weeks apart. 1, 25 It is important that all three aPL tests (LA, aCL and aβ2GP1) are performed as the aPL phenotype influences thrombotic risk. Triple aPL-positivity (i.e. the presence of LA, IgM and/or IgG aβ2GP1 and IgM and/or IgG aCL positivity) is correlated with the highest risk of thrombosis. 16 Medium to high titres are considered to be clinically significant for thrombosis, 1,30 whereas low IgM or IgG titres are not, although they may be relevant for pregnancy morbidity. 31 Indeed, the role of IgM aCL and aβ2GP1 is uncertain. Two meta-analyses were unable to evaluate IgM antibodies as a single serologic marker, because of unavailability of separate IgG and IgM results. 32 A multicentre study reported that there was no added value in testing for IgM in thrombotic APS (although the data supported testing in obstetric APS), but, combined positivity for LA, IgG, and IgM was highly associated with thrombosis and pregnancy morbidity, therefore IgM could be useful for risk stratification. However, only 55 patients had arterial thrombosis. 33 The results of LA testing in the acute thrombotic situation should be interpreted with caution as there may be false positives due to raised factor VIII, 34 false negatives due to raised C-reactive protein 35 and J o u r n a l P r e -p r o o f false negatives or positives related to concomitant anticoagulation. 36 Postinfection aPL are usually transient and generally unassociated with thrombosis. 37 A frequent single LA positivity during (acute phase) has been observed in COVID-19 infection but is not clearly related to thrombotic complications. Triple aPL positivity and high aCL/aβ2GPI titres are rare. Repeat testing suggests aPL are mostly transient. 38 The timing of LA testing following a first VTE (where DOACs are standard treatment), is pertinent. The 16 th International Congress on aPL treatment trends task force report advises that: it may be preferable to defer screening for aPL for most patients with a new VTE in the acute setting. For those patients in whom there is clinical concern for APS, however (e.g., patients with a new VTE and obstetric or non-criteria manifestations of APS), testing can be performed with appropriate interpretation of the laboratory results. 39 Several noncriteria aPL, such as antibodies against the domain 1 of aβ2GP1 and antiphosphatidylserine-prothrombin, and IgA aCL and aβ2GP1 have been studied. However, extended aPL testing (not widely available) is not recommended in routine practice as these antibodies do not have diagnostic utility, although they might aid in risk stratification. 28 Automated chemiluminescent assays have replaced ELISA for aCL and aβ2GP1: advantages of chemiluminescence include faster turnaround times, random access rather than batched assays, and improved reproducibility of results and inter-and intra-laboratory variation with automation. 40 High-avidity anti-protein C antibodies are associated with resistance to activated protein C and may provide a marker for a severe thrombotic phenotype in APS. 41 Warfarin or other vitamin K antagonists (VKAs) at therapeutic intensity are the standard treatment for thrombotic APS. The European Medicines Agency (EMA) has recommended that direct oral anticoagulants (DOACs) should not be used in APS, especially those that are triple aPL-positive. 42 This recommendation, which followed a risk assessment triggered by the TRAPS (Rivaroxaban in Thrombotic APS) trial, 43 has been widely adopted by regulatory authorities internationally. It should be noted that the EMA recommendation does not constitute a contraindication to the use of DOACs in APS. 44 J o u r n a l P r e -p r o o f Journal Pre-proof Direct oral anticoagulants are the standard treatment for a first VTE 24,39,44 episode in general population patients, based on large phase 3 trials. 45 The prevalence of aPL following a first unprovoked VTE is 9%, 27,46 and thus it is likely that many of these patients will have undiagnosed APS, without any reported increased risk of thrombosis. Table 2 Clinical practice points (see Table 2 for further details)  For triple aPL-positive patients on a DOAC for first VTE as standard of care, explain to the patient that it is recommended that the DOAC is switched to a VKA. For those who elect to remain on a DOAC, clinical surveillance, is important. This might include magnetic resonance imaging (MRI) brain imaging to identify ischaemic lesions, which if present merit consideration of a switch to an alternative anticoagulant, with the first option a VKA. 39 The prevalence of stroke and TIA at presentation with APS in a prospective cohort of 1000 patients was 13.1% and 7.0%, respectively. 52 Twenty percent of APS patients in this cohort developed a stroke. 53 Approximately 17% of strokes in patients under the age of 50 are associated with aPL 54 The spectrum of ischaemic brain lesions in APS encompasses white matter hyperintensities (WMH) of presumed vascular origin 55 which have face validity, being associated with clinically important outcomes of stroke, dementia and death. 56,57 APS patients are also at increased risk of myocardial infarction (MI), 58 with aPL reported in 11% of patients with MI. 59 Other arterial thrombotic events such as renal artery thrombosis 60 and peripheral arterial ischaemia 61 can occur. Table 2 provides a summary of current guidance for anticoagulation, including intensity, and antiplatelet treatment. VKAs remain the standard of care, although the optimal anticoagulation intensity is unknown. The variability in the guidance reflects the lack of appropriate, adequately powered studies to guide optimal antithrombotic and/or antiplatelet treatment in APS patients with arterial thrombotic manifestations. Two randomised controlled trials 47,48 concluded that the optimal target INR for thrombotic APS is 2.5 Laboratory criteria for aPL did not follow the international consensus criteria for a diagnosis of APS. 1 The TRAPS trial compared rivaroxaban 20mg once daily with warfarin, target INR 2.5, in 120 triple aPL-positive thrombotic APS patients. 43 Seven patients in the rivaroxaban arm (approximate annualised recurrent thrombosis rate 7.6%) had new arterial thrombotic events (four ischaemic stroke and three myocardial infarctions) compared with 0% in the warfarin arm. Four of the seven patients had previous arterial thrombosis. 43 A systematic review of 16 studies on secondary thromboprophylaxis in patients with aPL found that most recurrent thromboses (venous and arterial) occur in patients not receiving anticoagulation, or on antiplatelet treatment alone. Recurrent events were least likely to occur in those on warfarin, INR >3. 63 A recent meta-analysis reported that patients with APS who had an initial arterial thrombotic event had a recurrence rate over 2 years of 16% and 18% when taking anticoagulation or aspirin alone, respectively. The majority of patients taking anticoagulation were taking either a DOAC at a standard therapeutic dose, or warfarin with an INR range of 2.0-3.0. 64 The numbers of patients on DOAC versus VKA were not specified. The doses of DOACs reported in the literature in APS patients have been shown to be efficacious vs. standard-intensity warfarin in the phase three trials in general population patients with a first VTE. 45 These doses may not however, be effective to prevent arterial thrombosis. 65 The RISAPS (Rivaroxaban in Stroke Patients with APS) phase 2/3 RCT aims to assess the efficacy of high-intensity rivaroxaban 15mg twice daily versus high-intensity warfarin, target INR 3.5 (range 3.0-4.0) in patients with APS with previous ischemic stroke or other ischemic brain manifestations (https://clinicaltrials.gov/ct2/show/NCT03684564). Clinical practice points (see Table 2 Small vessel thrombosis is best described in the context of catastrophic antiphospholipid syndrome (CAPS), where it is a defining criteria, 66,67 but is outwith the scope of this review. Small vessel thrombosis also occurs in the subacute/chronic setting, although the literature in this area is scant. Histology is desirable for diagnostic accuracy, but is not always feasible depending on the risk of biopsy which varies with site, severity of illness and bleeding risk. 66 Thrombosis of the major renal arteries or veins can occur, but small vessel disease affecting the kidneys is a distinct phenomenon known as APS-related nephropathy. 68, 69 This is characterised by acute thrombosis and/or chronic arterial and arteriolar change, and is distinct from the changes of lupus nephritis. 4 Hypertension, proteinuria, hematuria, and renal insufficiency are the most common manifestations of APS-related nephropathy. 69 Small vessel thrombosis can have cutaneous manifestations, for example cutaneous digital gangrene, or necrotic skin ulceration which on biopsy is disease, skin ulceration, aPL nephropathy, and/or cognitive dysfunction reported that rituximab showed benefit for some non-criteria manifestations, notably skin ulceration and cognitive dysfunction, with the safety in aPL positive patients consistent with the safety profile of rituximab. The authors concluded that despite no substantial change in aPL profiles, rituximab may be effective in controlling some but not all non-criteria manifestations of APS. 79 Clinical practice points  Management is empirical and rituximab merits consideration  Anticoagulation to be considered if small vessel thrombosis might be implicated Anticoagulant-refractory APS is defined as thrombotic APS implies breakthrough thrombosis on therapeutic anticoagulation. This is a different entity to recurrent thromboses that occur due to a subtherapeutic INR, which could be related to non-adherence or a spurious therapeutic INR due to LA effect on thromboplastin producing a false elevation of the INR. 80 If re-thrombosis occurs while on therapeutic intensity VKA, further management is empirical and extrapolated from management of similar situations in patients with other disorders, such as cancer related thrombosis. 74 Antithrombotic treatment options include high intensity VKA, LMWH and fondaparinux, with or without the addition of an antiplatelet agent (see Figure 1 ). arterial. 16 Recurrent thrombosis rates in two RCTs evaluating standard-intensity versus high-intensity warfarin were 3.4% (2/58) and 10.7% (6/56); 48 and 5.5% (3/55) and 11.1% (6/54) 47 in the standard and high intensity warfarin arms, respectively. Notably, in the first study, the majority (6/8) of recurrent thrombotic events occurred while the INR was <3.0. 48 In the second study recurrent thrombosis was observed in 6/54 (11.1%) assigned to high-intensity warfarin and 3/55 (5.5%) to standard-intensity, but the INR at the time of re-thrombosis was not reported. 47 In consideration of recurrent thrombosis on parenteral anticoagulation, one study evaluated the use of LMWH in venous or arterial disease 24 APS patients, 16 of these had failed warfarin therapy. It highlighted that LMWH was safe and effective alternative. 81 A further retrospective review examined the use of LMWH in 23 APS patients who had intolerance or lack of response to warfarin. The mean duration of LMWH therapy was 36 months. Only three patients treated with LMWH had no clinical improvement/recurrent thrombosis suggesting the LMWH may be an alternative to warfarin. 82 Fondaparinux, a synthetic analogue of heparin pentasaccharide required for antithrombin binding, is considered when warfarin and LMWH have failed. We reported the use of fondaparinux in four patients with refractory thrombosis, three of which had APS who remained event free over 40 months of follow-up. 83 Clinical practice points (see Table 3 for further details)  Suspected recurrent thrombosis requires appropriate objective imaging and documentation with comparison made with previous available imaging where possible  If the patient is being treated with a VKA, the INR at the time of recurrence guides assessment of whether it is representative of true anticoagulation intensity. Chromogenic factor X levels provide an LA-independent measure of anticoagulation intensity but are not widely available and a therapeutic range is not established 80  Additional provoking factors for thrombosis need to be considered, such as malignancy.  Prior to making any adjustment to anticoagulation treatment, reassessment of bleeding risk factors, evaluation of full blood count, renal function and weight, to inform appropriate anticoagulation dosing  Following recurrent thrombosis while on therapeutic VKA options include high-intensity VKA, LMWH, fondaparinux and/or addition of antiplatelet treatment. In those who rethrombose on a DOAC, an additional option is standard-intensity VKA  If recurrent thrombosis occurs on standard-treatment dose LMWH, this may be increased by one-quarter to one-third, 84,85 using split dose (i.e divided total dose given twice-daily) and consideration of monitoring with anti-Xa levels Table 4 outlines the adjunctive treatment options for the management of APS-related thrombosis. The clinical manifestations of obstetric APS include three or more consecutive pregnancy losses at less than ten-week gestation, one or more fetal death at ≥ 10 weeks gestation or ≥ one preterm J o u r n a l P r e -p r o o f delivery for severe preeclampsia and/or placental insufficiency. The pathogenesis of this condition is not yet fully understood. The management consists of LMMH combined with an antiplatelet agent. A more detailed review of the management of obstetric APS has been published elsewhere. 86 We provide clinical guidance to facilitate the diagnosis and optimal management of thrombotic APS. Testing for aPL antibodies is appropriate in certain situations, notably where the provoking factor is disproportionately mild compared to the thrombotic event. APL testing whilst on anticoagulation is particularly challenging and requires careful education and discussion with patients. Arterial Protect against thrombosis through: -Inhibition of angiogenic factors in endothelial cells -Immunomodulatory effects on inflammatory activity so reducing endothelial damage -Inhibition of tissue factor expression and TLR-4 inhibition which blocks the signalling pathway of adapter protein MyDD88 in inflammatory cells, preventing synthesis of type 1 interferons -APS patients reported to have significantly lower vitamin D levels compared to normal controls -The thrombotic APS patients had a significantly lower levels of vitamin D than those with obstetric APS -Vitamin D deficiency identified in 50% of APS cohort compared with 30% in controls. --Thrombosis was noted in 77% of primary APS patients with vitamin D deficiency compared with 53% in those without vitamin D deficiency Hydroxychloroquine* HCQ has immunomodulatory and antithrombotic effects mediated through: -Inhibition of platelet aggregation by preventing the over expression of GPIIbIIIa on the membrane of aPL activated platelets. -It may also reduce binding of β2GP1 to the phospholipid bilayer of the target cell. -A systematic review found thrombotic events were prevented if antimalarials were taken consistently -A prospective, non-randomised study of 40 primary on HCQ + standard-intensity warfarin vs. VKA alone showed no recurrent thrombotic event in the HCQ cohort vs. 6 in those not receiving HCQ over 3 years Statins Fluvastatin and simvastatin can prevent aβ2GP1antibodies inducing endothelial cell adhesive properties via NF-κB binding to DNA which plays a central role in inflammation. Elevated levels of VEGF, soluble TF and TNF-α were identified in APS patients and that fluvastatin was able to significantly reduce those markers in the majority of treated patients Notes: *Hydroxychloroquine is standard treatment in patients with SLE if no contraindications. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) Phase II results Antiphospholipid syndrome nephropathy in systemic lupus erythematosus Systemic lupus erythematosus: Detailed anatomy of a cohort (follow-up for more than 35 years) High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus 189 epidemiology of antiphospholipid syndrome: A population-based study. 189 Epidemiology of antiphospholipid syndrome: a population-based study Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population The antiphospholipid syndrome The two hit hypothesis in the antiphospholipid syndrome: Acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS Genetics of antiphospholipid syndrome Genetic risk factors of thrombosis in the antiphospholipid syndrome The pathogenesis of the antiphospholipid syndrome Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms Pathogenesis of antiphospholipid syndrome: Understanding the antibodies Clinical course of high-risk patients diagnosed with antiphospholipid syndrome β2-Glycoprotein I: Evolution, structure and function Beta2-glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome Pathophysiology of thrombotic APS: Where do we stand? Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis The (non-) sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome Detection of shortened activated partial thromboplastin times: An evaluation of different commercial reagents Interference of C-reactive protein with clotting times Lupus anticoagulant detection in anticoagulated patients. guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the international society on thrombosis and haemostasis Environmental triggers of autoreactive responses: Induction of antiphospholipid antibody formation Antiphospholipid antibodies in patients with COVID-19: A relevant observation? 16th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. :Lupus The clinical performance of a new chemiluminescent immunoassay in measuring anti-beta2 glycoprotein 1 and anti-cardiolipin antibodies Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic Acute myocardial infarction and antiphospholipid antibody syndrome: A systematic review Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature Antiphospholipid syndrome nephropathy: From pathogenesis to treatment Antiphospholipid antibodies and lower extremity peripheral arterial disease-a systematic review and meta-analysis Antiphospholipid antibodies and subsequent thromboocclusive events in patients with ischemic stroke A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and Meta-Analysis Use of direct oral anticoagulants in antiphospholipid Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the -CAPS registry‖ Descriptive analysis of biopsy-proven antiphospholipid antibody-associated nephropathy patients included in the AntiPhospholipid syndrome alliance for clinical trials and InternatiOnal networking (APS ACTION) clinical database and repository (-Registry‖) Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS Cutaneous manifestations of antiphospholipid antibody syndrome Symmetric peripheral gangrene in antiphospholipid syndrome Pulmonary hypertension, antiphospholipid antibodies, and syndromes Multiple rib infarcts: A rare form of osteonecrosis in antiphospholipid syndrome Management of anticoagulantrefractory antiphospholipid syndrome Non-criteria manifestations of antiphospholipid syndrome. Lupus Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (II): Thrombocytopenia and skin manifestations Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: A longitudinal study Valvular heart disease in antiphospholipid syndrome A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: Communication from the SSC of the ISTH Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: Efficacy and safety-a preliminary report Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome The use of fondaparinux for recurrent thrombotic events Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report Antiphospholipid syndrome: Diagnosis and management in the obstetric patient Is there an additional value in detecting anticardiolipin and anti-β2 glycoprotein I IgA antibodies in the antiphospholipid syndrome? Thromb Haemost The clinical relevance of noncriteria antiphospholipid antibodies Guidelines on the investigation and management of antiphospholipid syndrome EULAR recommendations for the management of antiphospholipid syndrome in adults Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidencebased clinical practice guidelines The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome Vitamin D and J o u r n a l P r e -p r o o f Journal Pre-proof antiphospholipid syndrome Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome Antiphospholipid syndrome: Pathogenesis and a window of treatment opportunities in the future Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies: Effect on the proadhesive and proinflammatory phenotype Statins for the treatment of antiphospholipid syndrome?